[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549582":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":20,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":20,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Shenzhen Geno-Immune Medical Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MSC combined with 4SCAR T-cell therapy for autoimmune diseases","EXPERIMENTAL","nfusion of 4SCAR T cells at 10\\^6 cells\u002Fkg body weight and MSCs at 3x10\\^6 cells via IV",[13],"Biological: fetal MSCs combined with 4SCAR T cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","fetal MSCs combined with 4SCAR T cells","Infusion of 4SCAR T cells at 10\\^6 cells\u002Fkg body weight and MSCs at 3x10\\^6 cells via IV",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Lung-Ji Chang, PhD","CONTACT","+86 0755-86573763","c@szgimi.org",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Shenzhen Geno-immune Medical Institute","RECRUITING","Shenzhen","Guangdong","518000","China","CN",{"type":37,"coordinates":38},"Point",[39,40],114.0683,22.54554,{"lat":40,"lon":39},[43],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":45,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100549582","phase-1-autoimmune-disease-treatment-with-mesenchymal-stem-cells-mscs-and-car-t-cells-100549582",false,"NCT06435897","Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells","Management of Autoimmune Conditions With Mesenchymal Stem Cells (MSCs) and CAR-T Cells","Inclusion Criteria:\n\n1. older than 18 years of age.\n2. established autoimmune conditions.\n3. the KPS score over 80 points, and survival time is more than 3 months.\n4. greater than Hgb 80 g\u002FL.\n5. no contraindications to blood cell collection.\n\nExclusion Criteria:\n\n1. accompanied with other active diseases and difficult to assess treatment response.\n2. bacterial, fungal, or viral infection, unable to control.\n3. living with HIV.\n4. active HBV or HCV infection.\n5. pregnant and nursing mothers.\n6. under systemic steroid treatment within a week of the treatment.\n7. prior failed CAR-T treatment.","ALL","18 Years","75 Years",{"count":57,"type":58},30,"ESTIMATED","INTERVENTIONAL",[61,62],"PHASE1","PHASE2","The purpose of this study is to assess the feasibility, safety and efficacy of mesenchymal stem cells (MSCs) in combination with CAR-T cells in treating autoimmune disease. Another goal of the study is to learn more about the safety and function of the MSCs combined with CAR-T cells and their long term effects in autoimmune disease patients.",[65],"Autoimmune Diseases",[67,68,69,70,71,72,73,74],"CAR-T","MSC","autoimmune disease","autoantibody","B cell","plasma cell","CD19","BCMA","2026-06-18",{"date":77,"type":78},"2026-06-23","ACTUAL",{"date":80,"type":78},"2024-05-15",{"date":82,"type":58},"2027-12-31",{"name":5,"class":6},1]